MaxCyte EBIT

The latest EBIT for MXCT is $-34M as of June 2026. That compares with $-50M in the prior-year period — up 31.0% year over year. That is below the Materials sector average of $140B. Investors often review this figure alongside MaxCyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, MXCT's EBIT moved from $-50M to $-34M — a 31.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MaxCyte's operating scale or balance-sheet position.

Against Materials companies, MXCT currently prints $-34M for EBIT, while the sector average sits near $140B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at MaxCyte's growth, margins, and balance sheet.

A EBIT figure of $-34M for MXCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Materials average is about $140B. Explore the charts below for those layers of context.

After noting MXCT's EBIT ($-34M), review year-over-year change from $-50M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.